New Assay Improves Detection Of Deadly Prion Diseases
|
By LabMedica International staff writers Posted on 28 Apr 2016 |

Image: The FLUOstar Omega microplate reader (Photo courtesy of BMG Labtech).
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a family of rare progressive, neurodegenerative illnesses that affect both humans and animals and TSE surveillance is important for public health and food safety.
Because TSEs have the potential of crossing from animals to humans, as seen with the spread of mad cow disease, or bovine spongiform encephalopathy (BSE), an advanced assay that offers better sensitivity than currently available tests for detecting a prion disease is essential.
Scientists at the Lethbridge Laboratory (AB, Canada) studied elk brains from animals suffering from chronic wasting disease, a prion disease that affects cervids, which are hoofed ruminant mammals in the deer family, as the model for the assay. Surveillance programs rely on highly sensitive diagnostic methods to detect infections early. Addressing the need to define steadfast analytical performance criteria for prion amyloid seeding assays (ASAs), they developed a method to measure prion protein conversion time (from normal cellular form to prion form) by a combination of statistical analyses to obtain a prion-detecting ASA with a known degree of confidence.
The timed prion seeding assay (tASA) is an in vitro method that mimics the conjectured mechanism of prion propagation in vivo. It is a conversion assay that uses recombinant prion-related protein as a substrate and detects conversion via changes in fluorescence. The team described time specifications for the assay to help avoid false-positive results (30 hours) or false-negative results in weakly positive samples (48 hours), as well as the number of replications necessary for adequate sensitivity (two to 12). The assay is analyzed on a FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany).
They compared the sensitivity of the new assay technique, the tASA to other currently available tests: two bioassays in laboratory rodents and three commercially available TSE rapid tests. The three regulatory-approved TSE rapid test platforms were the Prionics Check WESTERN (Thermo Fisher Scientific, Waltham, MA, USA); the Bio-Rad TeSeE enzyme-linked immunosorbent assay (ELISA, Hercules, CA, USA); and the IDEXX HerdChek CWD enzyme-linked immunoassay (EIA, IDEXX, Westbrook, ME, USA).
The investigators were able to define clear cut-off criteria, allowing determination of TSE-positive and TSE-negative states. Unlike TSE rapid tests, ASAs also have the potential to detect and measure TSE infection in blood, saliva, or urine. This would offer clinical advantages, such as the ability to sample blood instead of relying on more invasive tissue biopsy and to screen blood donations for contamination.
John G. Gray, MS, the lead author of the study said, “We found that the tASA was at least as sensitive as two rodent bioassays and up to 16 times more sensitive than three different TSE rapid tests. We believe this methodology represents the future for prion diagnostics, especially concerning human health, for example in screening blood donations.” The study will be published on April 8, 2016, in The Journal of Molecular Diagnostics.
Related Links:
Lethbridge Laboratory
BMG Labtech
Thermo Fisher Scientific
Bio-Rad Laboratories
IDEXX
Because TSEs have the potential of crossing from animals to humans, as seen with the spread of mad cow disease, or bovine spongiform encephalopathy (BSE), an advanced assay that offers better sensitivity than currently available tests for detecting a prion disease is essential.
Scientists at the Lethbridge Laboratory (AB, Canada) studied elk brains from animals suffering from chronic wasting disease, a prion disease that affects cervids, which are hoofed ruminant mammals in the deer family, as the model for the assay. Surveillance programs rely on highly sensitive diagnostic methods to detect infections early. Addressing the need to define steadfast analytical performance criteria for prion amyloid seeding assays (ASAs), they developed a method to measure prion protein conversion time (from normal cellular form to prion form) by a combination of statistical analyses to obtain a prion-detecting ASA with a known degree of confidence.
The timed prion seeding assay (tASA) is an in vitro method that mimics the conjectured mechanism of prion propagation in vivo. It is a conversion assay that uses recombinant prion-related protein as a substrate and detects conversion via changes in fluorescence. The team described time specifications for the assay to help avoid false-positive results (30 hours) or false-negative results in weakly positive samples (48 hours), as well as the number of replications necessary for adequate sensitivity (two to 12). The assay is analyzed on a FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany).
They compared the sensitivity of the new assay technique, the tASA to other currently available tests: two bioassays in laboratory rodents and three commercially available TSE rapid tests. The three regulatory-approved TSE rapid test platforms were the Prionics Check WESTERN (Thermo Fisher Scientific, Waltham, MA, USA); the Bio-Rad TeSeE enzyme-linked immunosorbent assay (ELISA, Hercules, CA, USA); and the IDEXX HerdChek CWD enzyme-linked immunoassay (EIA, IDEXX, Westbrook, ME, USA).
The investigators were able to define clear cut-off criteria, allowing determination of TSE-positive and TSE-negative states. Unlike TSE rapid tests, ASAs also have the potential to detect and measure TSE infection in blood, saliva, or urine. This would offer clinical advantages, such as the ability to sample blood instead of relying on more invasive tissue biopsy and to screen blood donations for contamination.
John G. Gray, MS, the lead author of the study said, “We found that the tASA was at least as sensitive as two rodent bioassays and up to 16 times more sensitive than three different TSE rapid tests. We believe this methodology represents the future for prion diagnostics, especially concerning human health, for example in screening blood donations.” The study will be published on April 8, 2016, in The Journal of Molecular Diagnostics.
Related Links:
Lethbridge Laboratory
BMG Labtech
Thermo Fisher Scientific
Bio-Rad Laboratories
IDEXX
Latest Technology News
- Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
- New qPCR Master Mixes Offer Broad Compatibility for Routine Research
- Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
- Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
- Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
- AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
- Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows
- New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
- Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
- Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
- New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
- ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
- Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
- New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
- Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
- Autonomous Robotic System Receives FDA Authorization for Blood Collection
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







